Al-Dujaily Esraa A, Al-Janabi Asad A, Pierscionek Tomasz, Yasseen Akeel A
Department of Pathology and Forensic Medicine, Faculty of Medicine, Kufa, University, Kufa, P.O. Box 18, Iraq, .
J Carcinog. 2008;7:8. doi: 10.4103/1477-3163.44026.
This study aimed to estimate the rate of HER-2/neu (c-erbB2) immunohistochemical overexpression in different histological types of breast cancer found in the middle Euphrates region of Iraq, a region that was exposed to high levels of depleted uranium. HER-2/neu (c-erbB2) overexpression was correlated with common clinicopathological parameters such as age, grade, stage, tumor size and lymph node involvement to determine if any particular biomarker for exposure to depleted uranium could be found in the tumor samples from this region.
The present investigation was performed over a period starting from September 2007 to June 2008. Formalin-fixed, paraffin-embedded blocks from 90 patients with breast cancer were included in this study. A group of 25 patients with benign breast lesions (fibroadenoma) was included as a comparative group, and 20 breast tissue sections were used as controls. Labeled streptavidin-biotin (LSAB) complex method was employed for immunohistochemical detection of HER-2/neu.
HER-2/neu immuno-expression was positive in 67.8% of breast cancer, while it was negative in all benign breast lesions (fibroadenoma) ( P P P > 0.05).
Based upon the findings of this study, it can be concluded that HER-2/neu overexpression plays an important role in the pathogenesis of breast cancer and is associated with a worse prognosis. The findings indicate that in regions exposed to high levels of depleted uranium, HER-2/neu overexpression is high, but its correlation with age, grade, stage, tumor size, and lymph node involvement is similar to studies that have been conducted on populations not exposed to depleted uranium.
本研究旨在评估伊拉克幼发拉底河中游地区发现的不同组织学类型乳腺癌中HER-2/neu(c-erbB2)免疫组化过表达的发生率,该地区曾遭受高剂量贫铀暴露。HER-2/neu(c-erbB2)过表达与年龄、分级、分期、肿瘤大小和淋巴结受累等常见临床病理参数相关,以确定在该地区的肿瘤样本中是否能找到任何特定的贫铀暴露生物标志物。
本研究于2007年9月至2008年6月期间进行。本研究纳入了90例乳腺癌患者的福尔马林固定、石蜡包埋组织块。一组25例乳腺良性病变(纤维腺瘤)患者作为比较组,20例乳腺组织切片用作对照。采用标记链霉亲和素-生物素(LSAB)复合物法进行HER-2/neu的免疫组化检测。
HER-2/neu免疫表达在67.8%的乳腺癌中呈阳性,而在所有乳腺良性病变(纤维腺瘤)中均为阴性(P P P>0.05)。
基于本研究结果,可以得出结论,HER-2/neu过表达在乳腺癌发病机制中起重要作用,且与较差的预后相关。研究结果表明,在高剂量贫铀暴露地区,HER-2/neu过表达率较高,但其与年龄、分级、分期、肿瘤大小和淋巴结受累的相关性与未暴露于贫铀人群的研究相似。